Mancini Anthony 4

What Happened
Anthony Mancini, Chief Global Commercialization Officer at Revolution Medicines (RVMD), exercised stock options to acquire 3,121 shares at $33.62 each (cash paid: $104,928) on May 26, 2026. On the same day he sold 3,121 shares in multiple open-market transactions under a pre-established 10b5-1 plan, generating total proceeds of approximately $480,611 (sales executed at weighted-average prices shown below). The activity includes the conversion/settlement of the derivative (exercise) and immediate disposals.

Key Details

• Transaction date: 2026-05-26 (Form 4 filed 2026-05-28 — timely)
• Option exercise (Code M): 3,121 shares acquired at $33.62 — $104,928 total.
• Sales (Code S): 700 shares @ $153.30 = $107,312; 2,000 shares @ $154.06 = $308,122; 421 shares @ $154.82 = $65,177. Total proceeds ≈ $480,611.
• Derivative line: 3,121 shares reported as disposed at $0.00 reflects the equity conversion related to the option exercise.
• Sales executed under a 10b5-1 trading plan adopted December 24, 2025 (Footnote F1). Several trades were executed in multiple fills; reported prices are weighted averages (Footnotes F3–F5).
• Holdings after the transactions are not specified in the provided extract; filing notes holdings include 54,400 restricted stock units (Footnote F2). Vesting schedule for the option is described in Footnote F6.

Context
This was an option exercise paired with immediate sales (common mechanics include using a 10b5-1 plan to sell shares after exercising). The exercise lowered the strike exposure (purchase at $33.62) while the sales monetized shares at market prices (~$153–$155). The presence of a 10b5-1 plan indicates the sales were pre-arranged and routine; no inference about insider sentiment should be made from this single filing.